| GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet PL McClean, N Irwin, RS Cassidy, JJ Holst, VA Gault, PR Flatt American Journal of Physiology-Endocrinology and Metabolism 293 (6), E1746-E1755, 2007 | 271 | 2007 |
| Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease PL McClean, VA Gault, P Harriott, C Hölscher European journal of pharmacology 630 (1-3), 158-162, 2010 | 233 | 2010 |
| Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain A Hamilton, S Patterson, D Porter, VA Gault, C Holscher Journal of neuroscience research 89 (4), 481-489, 2011 | 227 | 2011 |
| Val (8) GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice S Gengler, PL McClean, R McCurtin, VA Gault, C Hölscher Neurobiology of aging 33 (2), 265-276, 2012 | 202 | 2012 |
| GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid VA Gault, C Hölscher European journal of pharmacology 587 (1-3), 112-117, 2008 | 193 | 2008 |
| Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3) GIP administration improves glucose tolerance and ameliorates insulin resistance and … VA Gault, N Irwin, BD Green, JT McCluskey, B Greer, CJ Bailey, P Harriott, ... Diabetes 54 (8), 2436-2446, 2005 | 191 | 2005 |
| Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1 BD Green, N Irwin, NA Duffy, VA Gault, FPM O'harte, PR Flatt European journal of pharmacology 547 (1-3), 192-199, 2006 | 174 | 2006 |
| Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary‐induced obesity and insulin resistance DW Porter, BD Kerr, PR Flatt, C Holscher, VA Gault Diabetes, Obesity and Metabolism 12 (10), 891-899, 2010 | 173 | 2010 |
| Sitagliptin, a dipeptidyl peptidase‐4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline VA Gault, R Lennox, PR Flatt Diabetes, Obesity and Metabolism 17 (4), 403-413, 2015 | 156 | 2015 |
| Effects of the novel (Pro3)GIP antagonist and exendin(9–39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese … VA Gault, FPM O'harte, P Harriott, MH Mooney, BD Green, PR Flatt Diabetologia 46, 222-230, 2003 | 150 | 2003 |
| Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes … VA Gault, BD Kerr, P Harriott, PR Flatt Clinical science 121 (3), 107-117, 2011 | 142 | 2011 |
| Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat … VA Gault, PL McClean, RS Cassidy, N Irwin, PR Flatt Diabetologia 50, 1752-1762, 2007 | 136 | 2007 |
| Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents BD Green, VA Gault, FPM O'harte, PR Flatt Current pharmaceutical design 10 (29), 3651-3662, 2004 | 135 | 2004 |
| Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide VA Gault, FPM O'Harte, P Harriott, PR Flatt Biochemical and biophysical research communications 290 (5), 1420-1426, 2002 | 131 | 2002 |
| Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes VA Gault, PR Flatt, FPM O’Harte Biochemical and biophysical research communications 308 (2), 207-213, 2003 | 125 | 2003 |
| Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? VA Gault, FPM O’Harte, PR Flatt Neuropeptides 37 (5), 253-263, 2003 | 115 | 2003 |
| Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP (3-42), is a GIP receptor antagonist in vivo VA Gault, JC Parker, P Harriott, PR Flatt, FPM O'Harte Journal of Endocrinology 175 (2), 525-534, 2002 | 115 | 2002 |
| Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis E Faivre, VA Gault, B Thorens, C Hölscher Journal of neurophysiology 105 (4), 1574-1580, 2011 | 114 | 2011 |
| A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon … VA Gault, VK Bhat, N Irwin, PR Flatt Journal of Biological Chemistry 288 (49), 35581-35591, 2013 | 113 | 2013 |
| Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic … N Irwin, PL McClean, FPM O’harte, VA Gault, P Harriott, PR Flatt Diabetologia 50, 1532-1540, 2007 | 110 | 2007 |
